top of page

SUBSCRIBE TO OUR NEWSLETTER

THE LATEST NEWS IN CANCER CLINICAL RESEARCH

AT MEDSIR WE ARE DEDICATED TO OFFER THE MOST RELEVANT NEWS ON THE LATEST ADVANCEMENTS IN ONCOLOGY CLINICAL RESEARCH. FIND OUT THE LATEST NEWS ON ONCOLOGY RESEARCH, REGULATORY APPROVALS, EVENTS, SCIENTIFIC CONFERENCES AND MUCH MORE!

DOWNLOAD COMPANY DOSSIER

Search

With the industry facing increasing pressure to deliver faster, smarter, and more efficient clinical trials, MEDSIR enters SCOPE with a clear message: ‘Upgrading your pipeline. Faster.’ In this internal interview, Laura Calabuig, Business Development Director, shares MEDSIR’s perspective on why this moment matters, how the company’s unique model addresses real‑world development challenges

With the industry facing increasing pressure to deliver faster, smarter, and more efficient clinical trials, MEDSIR enters SCOPE with a clear message: ‘Upgrading your pipeline. Faster.’ In this internal interview, Laura Calabuig, Business Development Director, shares MEDSIR’s perspective on why this moment matters, how the company’s unique model addresses real‑world development challenges

“True agility starts with designing the right clinical trial from the beginning”

Feb 24 min read

The PHERGuide study demonstrates the utility of circulating tumor DNA (ctDNA) for the early detection and real-time monitoring of localized HER2+ breast cancer

The PHERGuide study demonstrates the utility of circulating tumor DNA (ctDNA) for the early detection and real-time monitoring of localized HER2+ breast cancer

The PHERGuide study demonstrates the utility of circulating tumor DNA (ctDNA) for the early detection and real-time monitoring of localized HER2+ breast cancer

Dec 11, 20255 min read

The results of the EMPRESS study show the activity of giredestrant in reducing tumor proliferation in ER+/HER2- breast cancer at early stages without the need for ovarian function suppression

The results of the EMPRESS study show the activity of giredestrant in reducing tumor proliferation in ER+/HER2- breast cancer at early stages without the need for ovarian function suppression

The results of the EMPRESS study show the activity of giredestrant in reducing tumor proliferation in ER+/HER2- breast cancer at early stages without the need for ovarian function suppression

Oct 20, 20253 min read

MEDSIR and Ataraxis AI Launch Research Collaboration to Evaluate AI-Powered Platform

MEDSIR and Ataraxis AI Launch Research Collaboration to Evaluate AI-Powered Platform

MEDSIR and Ataraxis AI Launch Research Collaboration to Evaluate AI-Powered Platform as a Predictive Tool in Breast Cancer Randomized Clinical Trials

Oct 2, 20253 min read

World Conference on Lung Cancer 2025 MEDSIR drives innovation in lung cancer with active brain metastases and promotes global collaboration at WCLC 2025

World Conference on Lung Cancer 2025 MEDSIR drives innovation in lung cancer with active brain metastases and promotes global collaboration at WCLC 2025

World Conference on Lung Cancer 2025 MEDSIR drives innovation in lung cancer with active brain metastases and promotes global collaboration at WCLC 2025

Sep 18, 20253 min read

New potential treatment strategy for brain metastases and leptomeningeal disease: HER3-DXd shows promising results in the phase II TUXEDO-3 study for patients with limited therapeutic options

New potential treatment strategy for brain metastases and leptomeningeal disease: HER3-DXd shows promising results in the phase II TUXEDO-3 study for patients with limited therapeutic options

New potential treatment strategy for brain metastases and leptomeningeal disease: HER3-DXd shows promising results in the phase II TUXEDO-3 study for patients with limited therapeutic options

May 30, 20254 min read

From Barcelona to Boston: MEDSIR Celebrates 13 Years Advancing Global Cancer Research Through Innovation and international Collaboration

From Barcelona to Boston: MEDSIR Celebrates 13 Years Advancing Global Cancer Research Through Innovation and international Collaboration

From Barcelona to Boston: MEDSIR Celebrates 13 Years Advancing Global Cancer Research Through Innovation and international Collaboration

Apr 22, 20252 min read

MEDSIR & Debiopharm Announce the First Patient Dosed in the WIN-B Trial Exploring the Combination of Debio 0123 & Gileads Trodelvy® in Advanced Breast Cancer

MEDSIR & Debiopharm Announce the First Patient Dosed in the WIN-B Trial Exploring the Combination of Debio 0123 & Gileads Trodelvy® in Advanced Breast Cancer

MEDSIR & Debiopharm Announce the First Patient Dosed in the WIN-B Trial Exploring the Combination of Debio 0123 & Gileads Trodelvy® in Advanced Breast Cancer

Feb 26, 20254 min read

MEDSIR strengthens its commitment to information security and privacy

MEDSIR strengthens its commitment to information security and privacy

MEDSIR strengthens its commitment to information security and privacy

Feb 19, 20251 min read

Highlights from San Antonio Breast Cancer Symposium 2024: Insights on locally advanced or metastatic HR-positive/HER2-negative breast cancer

Highlights from San Antonio Breast Cancer Symposium 2024: Insights on locally advanced or metastatic HR-positive/HER2-negative breast cancer

Highlights from San Antonio Breast Cancer Symposium 2024: Insights on locally advanced or metastatic HR-positive/HER2-negative breast cancer

CANCER RESEARCH

Dec 23, 20245 min read

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

Dec 12, 20247 min read

MEDSIR showcases the DEMETHER Study: advancing therapeutic de-escalation and more effective treatments for advanced breast cancer

MEDSIR showcases the DEMETHER Study: advancing therapeutic de-escalation and more effective treatments for advanced breast cancer

MEDSIR showcases the DEMETHER Study: advancing therapeutic de-escalation and more effective treatments for advanced breast cancer

Dec 5, 20245 min read

MEDSIR Academy: Shaping the Future of Oncology Clinical Research

MEDSIR Academy: Shaping the Future of Oncology Clinical Research

MEDSIR Academy: Shaping the Future of Oncology Clinical Research

Nov 25, 20243 min read

MEDSIR joins the IGCS 2024 annual meeting: expanding horizons towards gynecologic oncology

MEDSIR joins the IGCS 2024 annual meeting: expanding horizons towards gynecologic oncology

MEDSIR joins the IGCS 2024 annual meeting: expanding horizons towards gynecologic oncology

Oct 31, 20243 min read

MEDSIR takes part in the Nexus Conference to address the challenges and opportunities of geographic diversity in clinical trials

MEDSIR takes part in the Nexus Conference to address the challenges and opportunities of geographic diversity in clinical trials

MEDSIR takes part in the Nexus Conference to address the challenges and opportunities of geographic diversity in clinical trials

Oct 23, 20244 min read

Highlights from ESMO 2024: The Next Frontier in Oncology

Highlights from ESMO 2024: The Next Frontier in Oncology

Highlights from ESMO 2024: The Next Frontier in Oncology

Sep 25, 20244 min read

Brain metastases: an oncological challenge requiring innovative solutions and multidisciplinary approaches

Brain metastases: an oncological challenge requiring innovative solutions and multidisciplinary approaches

Brain metastases: an oncological challenge requiring innovative solutions and multidisciplinary approaches

Sep 20, 20244 min read

MEDSIR presents new studies at ESMO that advance treatment of patients with poor prognosis cancers

MEDSIR presents new studies at ESMO that advance treatment of patients with poor prognosis cancers

MEDSIR presents new studies at ESMO that advance treatment of patients with poor prognosis cancers

Sep 16, 20245 min read

Experts ensure that early detection and proper prevention are key to tackling the future challenges of cancer

Experts ensure that early detection and proper prevention are key to tackling the future challenges of cancer

Experts ensure that early detection and proper prevention are key to tackling the future challenges of cancer

Sep 12, 20246 min read

Highlights from the SNO/ASCO CNS Metastases Conference: unveiling new frontiers in cancer brain metastasis

Highlights from the SNO/ASCO CNS Metastases Conference: unveiling new frontiers in cancer brain metastasis

Highlights from the SNO/ASCO CNS Metastases Conference: unveiling new frontiers in cancer brain metastasis

Aug 14, 20243 min read

Integration of Artificial Intelligence in Oncology Research

Integration of Artificial Intelligence in Oncology Research

Integration of Artificial Intelligence in Oncology Research

Jul 18, 20242 min read

National Cancer Survivor Month

National Cancer Survivor Month

National Cancer Survivor Month

Jun 13, 20243 min read

MEDSIR’s PRIMED Study Shows Promising Results for Preventing Sacituzumab Govitecan related Side Effects in the Treatment of HER2-negative Advanced Breast Cancer

MEDSIR’s PRIMED Study Shows Promising Results for Preventing Sacituzumab Govitecan related Side Effects in the Treatment of HER2-negative Advanced Breast Cancer

MEDSIR’s PRIMED Study Shows Promising Results for Preventing Sacituzumab Govitecan related Side Effects in the Treatment of HER2-negative Advanced Breast Cancer

Jun 3, 20244 min read

Highlights from ESMO BREAST 2024: Insights on locally advanced or metastatic HR-positive/HER2-negative breast cancer

Highlights from ESMO BREAST 2024: Insights on locally advanced or metastatic HR-positive/HER2-negative breast cancer

Highlights from ESMO BREAST 2024: Insights on locally advanced or metastatic HR-positive/HER2-negative breast cancer

May 29, 20243 min read

2 3 4 5

bottom of page